BioCentury on BioBusiness,
Politics and Policy
SCOTUS pleases BIO, PhRMA, but Congress may seek more pharma money
Wake me in November
Monday, July 2, 2012
The Supreme Court's decision last week to leave the Patient
Protection and Affordable Care Act largely untouched assures key elements
fought for by the Pharmaceutical
Research and Manufacturers of America and the Biotechnology
Industry Organization will stand, at least until year end.
The ruling preserves PhRMA's
deal with the White House and the Senate Finance Committee to pay more than $80
billion in taxes, rebates and fees over 10 years in exchange for a larger
market, no rebates for beneficiaries who are eligible for both Medicare Part D
and Medicaid, and no drug importation. It also preserves the biosimilars
pathway and the 12-year exclusivity period for innovators that was a hot button
words displayed of
To read this article, you must be an Archives subscriber. Please choose one of the options below.
All contents Copyright © 1993-2015 BioCentury Publications, Inc. ALL RIGHTS RESERVED. All use of this Web Site and its contents is governed by the BioCentury User Agreement
. The contents of this Web Site are protected under U.S. and foreign copyright and intellectual property laws, and no part of this Web Site or its contents may be photocopied, reproduced or retransmitted in any form without the written consent of BioCentury, which may be requested from Reprints/Permissions
. BioCentury®; The Bernstein Report on BioBusiness™; The BioCentury 100™; The Clear Route to ROI™; Because Real Intelligence is Hard to Find™; BCIQ™; and BioPharma's Knowledge Center™; are trademarks of BioCentury Publications, Inc., P.O. Box 1246, San Carlos, CA 94070. SciBX® and SciBX: Science-Business eXchange® are trademarks of Nature America, Inc. that are jointly used by BioCentury Publications, Inc. and Nature America, Inc.
Whether you want an individual subscription or need a global group license, we have the products,
the experience and the customer support that biopharma executives, researchers, investors, service providers,
and industry stakeholders have trusted for nearly two decades.
Let our Subscriber Services team customize the best intelligence package available in the industry to meet your needs.
Free Trial 4 Weeks of Access
Get a 4-week free trial subscription to see the important articles you are missing.
Get 4 Weeks Free
Thanks for purchasing this article.
Please bookmark this url for future reference.
We have also sent you a confirming e-mail with a receipt and this same url for your
close [ X ]